66 related articles for article (PubMed ID: 11366114)
1. New nonnucleoside reverse transcriptase inhibitors.
GMHC Treat Issues; 1999 Feb; 13(2):10. PubMed ID: 11366114
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?
Kilby JM; Saag MS
Infect Agents Dis; 1994 Dec; 3(6):313-23. PubMed ID: 7534192
[TBL] [Abstract][Full Text] [Related]
3. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.
Murphy RL
AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
5. DPC-083. DuPont Pharmaceuticals.
Lim ML
Curr Opin Investig Drugs; 2001 Sep; 2(9):1209-12. PubMed ID: 11717806
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
7. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
8. Drug watch.
Whitson S
Posit Aware; 1999; 10(3):16-7. PubMed ID: 11366758
[TBL] [Abstract][Full Text] [Related]
9. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
De Clercq E
Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
[TBL] [Abstract][Full Text] [Related]
10. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
11. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
12. Second-generation drugs fight resistant virus.
STEP Perspect; 1999; 99(1):3. PubMed ID: 11367160
[TBL] [Abstract][Full Text] [Related]
13. Novel HIV-1 reverse transcriptase inhibitors.
Jochmans D
Virus Res; 2008 Jun; 134(1-2):171-85. PubMed ID: 18308412
[TBL] [Abstract][Full Text] [Related]
14. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
Guillemont J; Pasquier E; Palandjian P; Vernier D; Gaurrand S; Lewi PJ; Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers MH; Arnold E; Das K; Pauwels R; Andries K; de Béthune MP; Bettens E; Hertogs K; Wigerinck P; Timmerman P; Janssen PA
J Med Chem; 2005 Mar; 48(6):2072-9. PubMed ID: 15771449
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
Ghosn J; Chaix ML; Delaugerre C
AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
[TBL] [Abstract][Full Text] [Related]
17. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
Parkin NT; Gupta S; Chappey C; Petropoulos CJ
Antimicrob Agents Chemother; 2006 Jan; 50(1):351-4. PubMed ID: 16377709
[TBL] [Abstract][Full Text] [Related]
18. The latest antiviral news.
Vazquez E
Posit Aware; 1999; 10(2):44. PubMed ID: 11366851
[TBL] [Abstract][Full Text] [Related]
19. Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides.
Masuda N; Yamamoto O; Fujii M; Ohgami T; Fujiyasu J; Kontani T; Moritomo A; Orita M; Kurihara H; Koga H; Nakahara H; Kageyama S; Ohta M; Inoue H; Hatta T; Suzuki H; Sudo K; Shimizu Y; Kodama E; Matsuoka M; Fujiwara M; Yokota T; Shigeta S; Baba M
Bioorg Med Chem; 2004 Dec; 12(23):6171-82. PubMed ID: 15519161
[TBL] [Abstract][Full Text] [Related]
20. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]